HomeNVV1 • FRA
add
Novavax Inc
Nakaraang pagsara
€7.00
Sakop ng araw
€6.98 - €6.98
Sakop ng taon
€5.23 - €10.03
Market cap
1.34B USD
Average na Volume
1.96K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 147.14M | 66.61% |
Gastos sa pagpapatakbo | -9.76M | -128.05% |
Net na kita | 17.53M | 121.63% |
Net profit margin | 11.91 | 112.98% |
Kita sa bawat share | 0.11 | 121.33% |
EBITDA | 26.06M | 123.07% |
Aktuwal na % ng binabayarang buwis | 2.10% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 735.08M | -20.37% |
Kabuuang asset | 1.18B | -24.60% |
Kabuuang sagutin | 1.30B | -40.29% |
Kabuuang equity | -127.75M | — |
Natitirang share | 162.94M | — |
Presyo para makapag-book | -8.86 | — |
Return on assets | 4.44% | — |
Return on capital | 42.77% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 17.53M | 121.63% |
Cash mula sa mga operasyon | -39.48M | 77.20% |
Cash mula sa pag-invest | 20.48M | -85.78% |
Cash mula sa financing | -6.60M | -92.99% |
Net change in cash | -27.30M | 36.93% |
Malayang cash flow | -2.33M | 98.14% |
Tungkol
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Itinatag
1987
Headquarters
Website
Mga Empleyado
749
